Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Tremfya (guselkumab) to treat adults with ...

A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

DUBAI, 16th April 2025 (WAM) -- The Emirates Drug Establishment (EDE) has approved new indications for Guselkumab, making the UAE the second country globally to authorise the treatment for Crohn ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis ...